# Integra Lifesciences Holdings Corp: financial statements, quarterly

IART · Nasdaq · CIK 917520 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iart.md) · [Financials](/companies/iart/financials.md) · [Filings](/companies/iart/filings.md) · [Insiders](/companies/iart/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iart/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [397 d](/filings/0000917520-26-000011.md) | [369](/filings/0000917520-25-000041.md) | [418](/filings/0000917520-25-000074.md) | [381](/filings/0000917520-25-000096.md) | [443 d](/filings/0000917520-26-000011.md) | [383](/filings/0000917520-26-000041.md) | [416](/filings/0000917520-26-000058.md) | [402](/filings/0000917520-26-000077.md) | [435 d](/filings/0000917520-26-000011.md) | [392](/filings/0000917520-26-000041.md) | [419](/filings/0000917520-26-000058.md) | [411](/filings/0000917520-26-000077.md) |
| Cost of revenue | $m | [171 d](/filings/0000917520-26-000011.md) | [162](/filings/0000917520-25-000041.md) | [192](/filings/0000917520-25-000074.md) | [181](/filings/0000917520-25-000096.md) | [194 d](/filings/0000917520-26-000011.md) | [188](/filings/0000917520-26-000041.md) | [206](/filings/0000917520-26-000058.md) | [195](/filings/0000917520-26-000077.md) | [214 d](/filings/0000917520-26-000011.md) | [175](/filings/0000917520-26-000041.md) | [199](/filings/0000917520-26-000058.md) | [201](/filings/0000917520-26-000077.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [163 d](/filings/0000917520-26-000011.md) | [166](/filings/0000917520-25-000041.md) | [195](/filings/0000917520-25-000074.md) | [177](/filings/0000917520-25-000096.md) | [179 d](/filings/0000917520-26-000011.md) | [181](/filings/0000917520-26-000041.md) | [180](/filings/0000917520-26-000058.md) | [169](/filings/0000917520-26-000077.md) | [169 d](/filings/0000917520-26-000011.md) | [178](/filings/0000917520-26-000041.md) | [172](/filings/0000917520-26-000058.md) | [165](/filings/0000917520-26-000077.md) |
| Operating income | $m | [36.0 d](/filings/0000917520-26-000011.md) | [4.0](/filings/0000917520-25-000041.md) | [(3.0)](/filings/0000917520-25-000074.md) | [(8.2)](/filings/0000917520-25-000096.md) | [35.6 d](/filings/0000917520-26-000011.md) | [(15.5)](/filings/0000917520-26-000041.md) | [(513)](/filings/0000917520-26-000058.md) | [11.8](/filings/0000917520-26-000077.md) | [23.0 d](/filings/0000917520-26-000011.md) | [11.5](/filings/0000917520-26-000041.md) | [19.3](/filings/0000917520-26-000058.md) | [18.9](/filings/0000917520-26-000077.md) |
| Interest expense | $m | [13.8 d](/filings/0000917520-24-000022.md) | [13.6](/filings/0000917520-24-000061.md) | [18.7](/filings/0000917520-25-000074.md) | [19.4](/filings/0000917520-25-000096.md) | [19.0 d](/filings/0000917520-26-000011.md) | [18.8](/filings/0000917520-26-000041.md) | [21.0](/filings/0000917520-26-000058.md) | [22.7](/filings/0000917520-26-000077.md) | [23.7 d](/filings/0000917520-26-000011.md) | [22.5](/filings/0000917520-26-000041.md) | [23.0](/filings/0000917520-26-000058.md) | [23.0](/filings/0000917520-26-000077.md) |
| Income tax | $m | [9.0 d](/filings/0000917520-26-000011.md) | [(1.9)](/filings/0000917520-25-000041.md) | [(2.8)](/filings/0000917520-25-000074.md) | [(9.7)](/filings/0000917520-25-000096.md) | [3.1 d](/filings/0000917520-26-000011.md) | [(4.7)](/filings/0000917520-26-000041.md) | [(46.9)](/filings/0000917520-26-000058.md) | [(1.4)](/filings/0000917520-26-000077.md) | [6.0 d](/filings/0000917520-26-000011.md) | [2.2](/filings/0000917520-26-000041.md) | [0.3](/filings/0000917520-26-000058.md) | [0.8](/filings/0000917520-26-000077.md) |
| Net income | $m | [19.8 d](/filings/0000917520-26-000011.md) | [(3.3)](/filings/0000917520-25-000096.md) | [(12.4)](/filings/0000917520-25-000096.md) | [(10.7)](/filings/0000917520-25-000096.md) | [19.4 d](/filings/0000917520-26-000011.md) | [(25.3)](/filings/0000917520-26-000077.md) | [(484)](/filings/0000917520-26-000077.md) | [(5.4)](/filings/0000917520-26-000077.md) | [(1.7) d](/filings/0000917520-26-000011.md) | [(4.6)](/filings/0000917520-26-000077.md) | [4.5](/filings/0000917520-26-000077.md) | [14.9](/filings/0000917520-26-000077.md) |
| Diluted EPS | $ per share | not reported | [(0.04)](/filings/0000917520-25-000041.md) | [(0.16)](/filings/0000917520-25-000074.md) | [(0.14)](/filings/0000917520-25-000096.md) | not reported | [(0.33)](/filings/0000917520-26-000041.md) | [(6.31)](/filings/0000917520-26-000058.md) | [(0.07)](/filings/0000917520-26-000077.md) | not reported | [(0.06)](/filings/0000917520-26-000041.md) | [0.06](/filings/0000917520-26-000058.md) | [0.19](/filings/0000917520-26-000077.md) |
| Basic EPS | $ per share | not reported | [(0.04)](/filings/0000917520-25-000041.md) | [(0.16)](/filings/0000917520-25-000074.md) | [(0.14)](/filings/0000917520-25-000096.md) | not reported | [(0.33)](/filings/0000917520-26-000041.md) | [(6.31)](/filings/0000917520-26-000058.md) | [(0.07)](/filings/0000917520-26-000077.md) | not reported | [(0.06)](/filings/0000917520-26-000041.md) | [0.06](/filings/0000917520-26-000058.md) | [0.19](/filings/0000917520-26-000077.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [276](/filings/0000917520-25-000017.md) | [592](/filings/0000917520-24-000061.md) | [215](/filings/0000917520-24-000094.md) | [215](/filings/0000917520-24-000108.md) | [246](/filings/0000917520-26-000011.md) | [239](/filings/0000917520-25-000041.md) | [218](/filings/0000917520-25-000074.md) | [232](/filings/0000917520-25-000096.md) | [235](/filings/0000917520-26-000077.md) | [237](/filings/0000917520-26-000041.md) | [214](/filings/0000917520-26-000058.md) | [252](/filings/0000917520-26-000077.md) |
| Current assets | $m | [1,058](/filings/0000917520-25-000017.md) | [1,416](/filings/0000917520-24-000061.md) | [1,112](/filings/0000917520-24-000094.md) | [1,100](/filings/0000917520-24-000108.md) | [1,082](/filings/0000917520-26-000011.md) | [1,107](/filings/0000917520-25-000041.md) | [1,143](/filings/0000917520-25-000074.md) | [1,144](/filings/0000917520-25-000096.md) | [1,160](/filings/0000917520-26-000077.md) | [1,172](/filings/0000917520-26-000041.md) | [1,191](/filings/0000917520-26-000058.md) | [1,190](/filings/0000917520-26-000077.md) |
| Total assets | $m | [3,782](/filings/0000917520-25-000017.md) | [4,078](/filings/0000917520-24-000061.md) | [4,074](/filings/0000917520-24-000094.md) | [4,066](/filings/0000917520-24-000108.md) | [4,037](/filings/0000917520-26-000011.md) | [4,053](/filings/0000917520-25-000041.md) | [3,668](/filings/0000917520-25-000074.md) | [3,646](/filings/0000917520-25-000096.md) | [3,602](/filings/0000917520-26-000077.md) | [3,578](/filings/0000917520-26-000041.md) | [3,563](/filings/0000917520-26-000058.md) | [3,508](/filings/0000917520-26-000077.md) |
| Current liabilities | $m | [307](/filings/0000917520-25-000017.md) | [302](/filings/0000917520-24-000061.md) | [328](/filings/0000917520-24-000094.md) | [913](/filings/0000917520-24-000108.md) | [922](/filings/0000917520-26-000011.md) | [918](/filings/0000917520-25-000041.md) | [930](/filings/0000917520-25-000074.md) | [364](/filings/0000917520-25-000096.md) | [456](/filings/0000917520-26-000077.md) | [347](/filings/0000917520-26-000041.md) | [331](/filings/0000917520-26-000058.md) | [329](/filings/0000917520-26-000077.md) |
| Total liabilities | $m | [2,194](/filings/0000917520-25-000017.md) | [2,480](/filings/0000917520-24-000061.md) | [2,540](/filings/0000917520-24-000094.md) | [2,544](/filings/0000917520-24-000108.md) | [2,492](/filings/0000917520-26-000011.md) | [2,529](/filings/0000917520-25-000041.md) | [2,629](/filings/0000917520-25-000074.md) | [2,609](/filings/0000917520-25-000096.md) | [2,559](/filings/0000917520-26-000077.md) | [2,535](/filings/0000917520-26-000041.md) | [2,520](/filings/0000917520-26-000058.md) | [2,441](/filings/0000917520-26-000077.md) |
| Long-term debt | $m | [775](/filings/0000917520-24-000022.md) | [775](/filings/0000917520-24-000061.md) | [770](/filings/0000917520-24-000094.md) | [765](/filings/0000917520-24-000108.md) | [760](/filings/0000917520-25-000017.md) | [756](/filings/0000917520-25-000041.md) | [746](/filings/0000917520-25-000074.md) | [736](/filings/0000917520-25-000096.md) | [727](/filings/0000917520-26-000011.md) | [717](/filings/0000917520-26-000041.md) | [707](/filings/0000917520-26-000058.md) | [698](/filings/0000917520-26-000077.md) |
| Shareholders' equity | $m | [1,588](/filings/0000917520-26-000011.md) | [1,598](/filings/0000917520-25-000096.md) | [1,534](/filings/0000917520-25-000096.md) | [1,522](/filings/0000917520-25-000096.md) | [1,545](/filings/0000917520-26-000077.md) | [1,524](/filings/0000917520-26-000077.md) | [1,039](/filings/0000917520-26-000077.md) | [1,038](/filings/0000917520-26-000077.md) | [1,043](/filings/0000917520-26-000077.md) | [1,042](/filings/0000917520-26-000077.md) | [1,043](/filings/0000917520-26-000077.md) | [1,067](/filings/0000917520-26-000077.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [58.8 d](/filings/0000917520-26-000011.md) | [15.8](/filings/0000917520-25-000041.md) | [40.4 d](/filings/0000917520-25-000074.md) | [22.5 d](/filings/0000917520-25-000096.md) | [50.7 d](/filings/0000917520-26-000011.md) | [(11.3)](/filings/0000917520-26-000041.md) | [8.9 d](/filings/0000917520-26-000058.md) | [40.9 d](/filings/0000917520-26-000077.md) | [11.8 d](/filings/0000917520-26-000011.md) | [9.8](/filings/0000917520-26-000041.md) | [22.8 d](/filings/0000917520-26-000058.md) | [96.0 d](/filings/0000917520-26-000077.md) |
| Capital expenditure | $m | [24.5 d](/filings/0000917520-26-000011.md) | [15.5](/filings/0000917520-25-000041.md) | [29.7 d](/filings/0000917520-25-000074.md) | [29.6 d](/filings/0000917520-25-000096.md) | [29.6 d](/filings/0000917520-26-000011.md) | [28.9](/filings/0000917520-26-000041.md) | [20.1 d](/filings/0000917520-26-000058.md) | [15.2 d](/filings/0000917520-26-000077.md) | [17.2 d](/filings/0000917520-26-000011.md) | [14.8](/filings/0000917520-26-000041.md) | [12.3 d](/filings/0000917520-26-000058.md) | [10.2 d](/filings/0000917520-26-000077.md) |
| Share repurchases | $m | [0.0 d](/filings/0000917520-26-000011.md) | [0.0](/filings/0000917520-24-000061.md) | [50.0 d](/filings/0000917520-25-000074.md) | [0.0 d](/filings/0000917520-25-000096.md) | [2.5 d](/filings/0000917520-26-000011.md) | not reported | not reported | [0.0 d](/filings/0000917520-26-000077.md) | [0.0 d](/filings/0000917520-26-000011.md) | not reported | not reported | [0.0 d](/filings/0000917520-26-000077.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [82.3](/filings/0000917520-24-000061.md) | [81.2](/filings/0000917520-24-000094.md) | [79.8](/filings/0000917520-24-000108.md) | [77.7](/filings/0000917520-25-000041.md) | [77.4](/filings/0000917520-25-000074.md) | [76.4](/filings/0000917520-25-000096.md) | [76.5](/filings/0000917520-26-000041.md) | [76.7](/filings/0000917520-26-000058.md) | [76.8](/filings/0000917520-26-000077.md) | [77.0](/filings/0000917520-26-000041.md) | [78.2](/filings/0000917520-26-000058.md) | [78.6](/filings/0000917520-26-000077.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 77,800,976 at 2026-10-22, from the cover of the [10-Q filed 2026-10-23](/filings/0000917520-26-000077.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.